These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 22138210)

  • 21. Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients.
    Kumar D; Campbell P; Hoschler K; Hidalgo L; Al-Dabbagh M; Wilson L; Humar A
    Transplantation; 2016 Mar; 100(3):662-9. PubMed ID: 26335915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.
    Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli C; Groth N; Levin Y; Del Giudice G
    Hum Vaccin Immunother; 2014; 10(6):1701-10. PubMed ID: 24732325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children.
    Solares AR; Aragon CG; Pivaral RU; Prado-Cohrs D; Sales-Carmona V; Pellegrini M; Groth N
    J Infect Dev Ctries; 2014 Sep; 8(9):1160-8. PubMed ID: 25212080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults.
    Herbinger KH; von Sonnenburg F; Nothdurft HD; Perona P; Borkowski A; Fragapane E; Nicolay U; Clemens R
    Hum Vaccin Immunother; 2014; 10(1):92-9. PubMed ID: 24047817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children.
    Nolan T; Bravo L; Ceballos A; Mitha E; Gray G; Quiambao B; Patel SS; Bizjajeva S; Bock H; Nazaire-Bermal N; Forleo-Neto E; Cioppa GD; Narasimhan V
    Vaccine; 2014 Oct; 32(46):6146-56. PubMed ID: 25223266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis.
    Aikawa NE; Campos LM; Goldenstein-Schainberg C; Saad CG; Ribeiro AC; Bueno C; Precioso AR; Timenetsky Mdo C; Silva CA; Bonfá E
    Scand J Rheumatol; 2013; 42(1):34-40. PubMed ID: 22992045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly].
    Li RC; Fang HH; Li YP; Liu YP; Nong Y; Huang GB
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):548-51. PubMed ID: 19040034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.
    Vesikari T; Karvonen A; Tilman S; Borkowski A; Montomoli E; Banzhoff A; Clemens R
    Pediatrics; 2010 Oct; 126(4):e762-70. PubMed ID: 20819892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations.
    Hatz C; Cramer JP; Vertruyen A; Schwarz TF; von Sonnenburg F; Borkowski A; Lattanzi M; Hilbert AK; Cioppa GD; Leroux-Roels G
    Vaccine; 2012 Jul; 30(32):4820-7. PubMed ID: 22626675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major.
    Esposito S; D'Angelo E; Daleno C; Peia F; Scala A; Serra D; Mirra N; Galeone C; Principi N
    Vaccine; 2010 Nov; 28(50):7825-8. PubMed ID: 20888873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.
    de Bruijn I; Meyer I; Gerez L; Nauta J; Giezeman K; Palache B
    Vaccine; 2007 Dec; 26(1):119-27. PubMed ID: 18063446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
    Song JY; Cheong HJ; Noh JY; Seo YB; Choi WS; Cho GJ; Hwang TG; Kim WJ
    J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis.
    Black S; Della Cioppa G; Malfroot A; Nacci P; Nicolay U; Pellegrini M; Sokal E; Vertruyen A
    Vaccine; 2010 Oct; 28(45):7331-6. PubMed ID: 20813217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine.
    Podda A
    Vaccine; 2001 Mar; 19(17-19):2673-80. PubMed ID: 11257408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MF59-adjuvanted seasonal trivalent inactivated influenza vaccine: Safety and immunogenicity in young children at risk of influenza complications.
    Patel SS; Bizjajeva S; Heijnen E; Oberye J
    Int J Infect Dis; 2019 Aug; 85S():S18-S25. PubMed ID: 31051279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in children and adolescents with Williams or Cornelia De Lange syndrome.
    Esposito S; Selicorni A; Daleno C; Valzano A; Cerutti M; Galeone C; Consolo S; Menni F; Principi N
    Hum Vaccin; 2011 Jun; 7(6):613-7. PubMed ID: 21508673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of intradermal influenza vaccine in children.
    Esposito S; Daleno C; Picciolli I; Tagliaferri L; Scala A; Prunotto G; Montinaro V; Galeone C; Principi N
    Vaccine; 2011 Oct; 29(44):7606-10. PubMed ID: 21855592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
    Reisinger KS; Holmes SJ; Pedotti P; Arora AK; Lattanzi M
    Hum Vaccin Immunother; 2014; 10(8):2395-407. PubMed ID: 25424947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients.
    de Roux A; Marx A; Burkhardt O; Schweiger B; Borkowski A; Banzhoff A; Pletz MW; Lode H
    Vaccine; 2006 Mar; 24(10):1537-42. PubMed ID: 16288937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.